TNFRSF17 and plasma cell myeloma: For instance, in the case of anti-FAP CAR-T used to treat cardiac fibrosis in a mouse model, no notable adverse effects were observed 44, which is significantly different from anti-BCMA and anti-CD19 CAR-T in multiple myeloma 45.